BCN Biosciences is an early phase biotechnology corporation with core competencies in the oncology drug discovery market. BCN is currently developing novel chemical entities that affect cellular proliferation and cancer. BCN employs technology that can effectively mine novel structures from natural resources, thus maximizing molecular diversity for drug discovery. BCN is also focused on the development of therapeutic agents against a novel epidermal growth factor gene target highly expressed in tumor cells. Our experienced team of drug discovery and oncology experts backs our commitment to developing novel and effective medicines to prevent and treat cancer, one of world’s most serious diseases.

For more information contact: Andrew J. Norris Ph.D. or Sudip Chakrabortty
bcnbio.com